BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

The subcutaneous administration of the established immunotherapy could free up an estimated 30,000 hours of infusion chair ...

A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...

Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is indicated for the treatment of adult and paediatric patients 12 years and older with unresectable or metastatic microsatellite ...

In a significant regulatory development for cancer care in India, the Subject Expert Committee functioning under the Central ...

New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical giant focused on discovering, developing and delivering innovative medicines for serious diseases, with core areas ...

Bristol Myers BMY has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Opdivo is a key drug in BMY’s growth portfolio that ...